Jubilant Pharmova Share Price
Free Demat with Zero AMC*
+ Free 1st Year AMC
Summary
The stock has recorded a trading volume of 1,35,312 shares,. Its Average Traded Price (ATP) is ₹940.69, while the Last Traded Quantity at the Last Traded Price (LTQ@LTP) is 2 @ ₹933.60.
Jubilant Pharmova has an upper circuit limit of ₹1145.40 and a lower circuit limit of ₹763.60. The total value traded stands at ₹12.73 CR, and the delivery percentage for the day is 45.45%.
The stock is currently traded with a market lot size of 1. Jubilant Pharmova also offers a dividend yield of 0.52%.
Jubilant Pharmova Share Price Chart
Jubilant Pharmova Share Key Metrics
Volume
1.35 L
Market Cap
14870.49 CR
LTQ@LTP
2@933.60
ATP
940.69
Var Margin
16.22 %
Circuit Range
763.6-1145.4
Delivery %
45.45 %
Value
12.73 CR
ASM/GSM
No
Market Lot
1
Jubilant Pharmova Resistance and Support
Pivot 961.4
Resistance
First Resistance
980.1
Second Resistance
1005.7
Third Resistance
1024.4
Support
First Support
935.8
Second Support
917.1
Third Support
891.5
Jubilant Pharmova Shareholding Pattern
View More- 2016-17
- 2018-19
- 2019-20
- 2020-21
- 2021-22
- 2022-23
- 2023-24
- 2024-25
- 2025-26
- 2026-27
Total Promoters
Jubilant Pharmova Corporate Actions
| Date | Agenda |
|---|---|
| 2026-11-13 | Quarterly Results |
| 2026-08-10 | Quarterly Results |
| 2026-08-07 | Quarterly Results |
| 2026-05-22 | Audited Results & Final Dividend |
| 2026-02-06 | Quarterly Results |
| 2025-10-31 | Quarterly Results |
| 2025-07-29 | Quarterly Results |
| 2025-05-16 | Audited Results & Final Dividend |
| 2025-01-31 | Quarterly Results |
| 2024-10-25 | Quarterly Results |
| 2026-10-12 | To approve raising of funds |
| Ex Date | Record Date | |
|---|---|---|
| 2026-07-24 | 2026-07-24 | View More |
Jubilant Pharmova News
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jubilant Pharmova released its Q2 FY27 earnings press release, reporting a 21% YoY increase in revenue to Rs.2,370 crores. However, net profit declined by 74% to Rs.31 crores due to lower operating profitability, higher remediation costs at Montreal, and increased depreciation.
Nov 13 2026 20:23:40
Jubilant Pharmova Ltd - 530019 - Board Meeting Outcome for Meeting Held On November 13, 2026
Jubilant Pharmova reported its Q2 FY27 financial results, posting a 20.5% YoY increase in cons. revenue to ₹2,370 crore, while net profit fell 74% YoY to ₹31 crore. The company also highlighted its recent allotment of ₹800 crore unsecured NCDs on a private placement basis.
Nov 13 2026 20:13:11
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Jubilant Pharmova's step-down subsidiary, Jubilant Therapeutics, will present preliminary Phase 1 clinical data for JBI-802 at the 68th ASH Annual Meeting. The data highlights rapid platelet reductions, with all 8 patients at the 15 mg dose achieving >50% reduction by Week 3.
Nov 10 2026 20:20:43
Jubilant Pharmova Ltd - 530019 - Announcement under Regulation 30 (LODR)-Allotment
Jubilant Pharmova allotted 80,000 unsecured, listed, redeemable NCDs aggregating to Rs.800 crore on a private placement basis. The debentures carry an 8.50% annual coupon rate and have a tenure of 3 years.
Nov 05 2026 22:27:34
Jubilant Pharmova Ltd - 530019 - Disclosure Under Regulation 30 And Other Applicable Provisions Of The Securities And Exchange Board Of India (Listing Obligations And Disclosure Requirements) Regulations, 2015 - Allotment Of Non-Convertible Debentures (Ncds) On A Private Placement Basis-Rs.800 Crores
Jubilant Pharmova has approved the allotment of 80,000 unsecured NCDs on a private placement basis, aggregating to Rs.800 crores. The debentures carry an 8.50% interest rate and will mature on November 5, 2028.
Nov 05 2026 22:22:12
Jubilant Pharmova Ltd - 530019 - Board Meeting Intimation for Unaudited Standalone And Consolidated Financial Results Of The Company For The Quarter And Half Year Ended September 30, 2026
Jubilant Pharmova has scheduled a board meeting on 13 Nov 2026. The board will approve the financial results for the quarter and half-year ended 30 Sep 2026.
Oct 30 2026 17:18:39
Jubilant Pharmova Ltd - 530019 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Jubilant Pharmova has initiated a Postal Ballot to approve the issuance of Non-Convertible Debentures on a private placement basis for an aggregate amount up to ₹2,500 crores. The funds are earmarked for capital expenditure, debt refinancing, and strategic acquisitions, with e-voting closing on November 20, 2026.
Oct 21 2026 20:12:54
Jubilant Pharmova Management
| Name | Position |
|---|---|
| Naresh Kapoor | Company Secretary & Compliance Officer |
| Shyam S Bhartia | Chairman |
Jubilant Pharmova Similar Stocks
Molbio Diagnostics Ltd.
1497.60
13.50 (0.91%)
Poly Medicure Ltd.
1654.50
4.90 (0.30%)
Natco Pharma Ltd.
820.60
-2.30 (0.28%)
Vijaya Diagnostic Centre Ltd.
1533.60
66.20 (4.51%)
Marksans Pharma Ltd.
294.50
-11.60 (3.79%)
CORONA Remedies Ltd.
2256.20
-19.40 (0.85%)
Sudeep Pharma Ltd.
1202.20
-15.30 (1.26%)
Rainbow Children's Medicare Ltd.
1258.00
-12.40 (0.98%)
Alivus Life Sciences Ltd.
1444.70
-3.10 (0.21%)
Jubilant Pharmova FAQs
Open Your Free
Demat Account Now!
AMC for First Year
Auto Square Off Charges
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools

Open Your Free
Demat Account Now!
AMC For First Year
Account Opening Fee
+ Free 1st Year AMC
13 Lakh+ Clients
Expert-Backed
Premium Tools
Invest in JUBLPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade
+ Free 1st Year AMC
Or Download Choice FinX App
Invest in JUBLPHARMA
Account Opening Fee AMC for 1st Year Auto Square Off Charges Call & Trade